Management of the Contralateral Testis in Patients with Testicular Germ Cell Cancer
- 1 March 1990
- journal article
- research article
- Published by Wiley in British Journal of Urology
- Vol. 65 (3) , 290-293
- https://doi.org/10.1111/j.1464-410x.1990.tb14731.x
Abstract
Summary— Patients with testicular germ cell tumours (TGCT) are at increased risk of developing a tumour in the contralateral testis. Such a tumour may be preceded by carcinoma in situ (CIS), which is more common in patients with infertility, atrophic testis or a history of cryptorchism. Of 1219 patients with TGCT seen at the Royal Marsden Hospital between 1962 and 1984 in whom the contralateral testis was managed by surveillance, 38 (3.1%) developed a second tumour and 8 died of germ cell tumours. Seventeen of 26 assessable patients (65%) exhibited at least one of the known aetiological risk factors for carcinoma in situ. Diagnosis of carcinoma in situ may lead to more appropriate management of the contralateral testis.This publication has 12 references indexed in Scilit:
- Carcinoma in situ of the testis: aneuploid cells in semenBMJ, 1988
- CARCINOMA-IN-SITU GERM-CELLS EXFOLIATED FROM SEMINIFEROUS EPITHELIUM INTO SEMINAL FLUIDThe Lancet, 1988
- Management of carcinoma‐in‐situ of the testisInternational Journal of Andrology, 1987
- Carcinoma in situ of the contralateral testis.BMJ, 1987
- Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients.BMJ, 1986
- Screening for carcinoma in situ of the contralateral testis in patients with germinal testicular cancer.BMJ, 1982
- Bilateral Germ Cell Tumours of the TestisBritish Journal of Urology, 1980
- Fertility after Unilateral Orchidectomy and Radiotherapy for Patients with Malignant Tumours of the TestisBMJ, 1973
- POSSIBLE CARCINOMA-IN-SITU OF THE TESTISThe Lancet, 1972